Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562728 | 0.77 | HPRT1 (0.46) | SLC6A4SLC6A3HPRT1ALDH1A1TSHR | |
| SCHEMBL30366540 | 0.77 | HPRT1 (0.46) | SLC6A4SLC6A3HPRT1ALDH1A1TSHR | |
| SCHEMBL4246559 | 0.73 | CYP1A2 (0.59) | ALDH1A1TSHRKDM4EL3MBTL1HTT | |
| SCHEMBL182562 | 0.70 | — | — | |
| SCHEMBL30769070 | 0.70 | — | — | |
| SCHEMBL16917822 | 0.69 | HTR1B (0.42) | SLC6A4SLC6A3HPRT1ALDH1A1TSHR | |
| SCHEMBL19016682 | 0.69 | HPRT1 (0.37) | SLC6A4SLC6A3HPRT1ALDH1A1TSHR | |
| SCHEMBL155660 | 0.69 | PKM (0.40) | SLC6A4SLC6A3HPRT1ALDH1A1TSHR | |
| SCHEMBL1446076 | 0.69 | CES2 (0.36) | — | |
| SCHEMBL28136305 | 0.69 | PKM (0.40) | SLC6A4SLC6A3HPRT1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620102-B1 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-1423106-B1 | ARYLSULFONYL DERIVATIVES WITH 5-HT 6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| CN-1254469-C | Having a 5-HT6Receptor affinity arylsulfonyl derivatives | HOFFMANN LA ROCHE (CH) | 2006-05-03 | — | — | CN | disclosed |
| EP-1620102-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| US-6825202-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-30 | — | — | US | disclosed |
| WO-2004099150-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
| CN-1541210-A | Arylsulfonyl derivatives with 5-HT6 receptor affinity | - | 2004-10-27 | — | — | CN | disclosed |
| EP-1192165-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1423106-A1 | ARYLSULFONYL DERIVATIVES WITH 5-HT 6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20030069254-A1 | New arylsulfonyl derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2003014097-A1 | ARYLSULFONYL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-20 | — | — | WO | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | NFKBIA, IKBKB, NFKB2 | SLC6A4 4815/4885SLC6A3 4739/4885HPRT1 4752/4885 |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | SLC6A4 3684/4885SLC6A3 3204/4885HPRT1 3627/4885 |
| US-20030069254-A1 | New arylsulfonyl derivatives with 5-HT6 receptor affinity | HTR6, HTR1A, HTR4 | SLC6A4 20/4885SLC6A3 46/4885HPRT1 3394/4885 |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | HCAR2, PCCA, MCCC2 | SLC6A4 3678/4885SLC6A3 2924/4885HPRT1 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.